AI brief of an SEC Form 8-K · Perrigo (PRGO)

Perrigo names Matt Winterman EVP of Global Operations; Ron Janish to retire September 30

Neutral Impact 3 of 5 leadership Written later

Perrigo said its EVP of Global Operations and Supply Chain, Ron Janish, will step down effective June 23, 2025, and serve in an advisory role until September 30, 2025. Matt Winterman, previously SVP of Global Supply Chain and Strategy at AstraZeneca, will succeed him effective June 23, 2025. The filing discloses no financial results or guidance, and the executive change is a leadership transition for the operations function.

Key points

  • Ron Janish steps down as EVP, Global Operations and Supply Chain effective June 23, 2025, and advises the company until September 30, 2025.
  • Janish's separation severance is a lump sum of 2.5 times his base salary and target annual bonus, plus statutory redundancy payments and continued vesting of equity awards, subject to a general release of claims.
  • Matt Winterman takes the role effective June 23, 2025; he previously oversaw a $54 billion supply chain across 5,000 SKUs at AstraZeneca.
  • The press release gives Winterman's title as EVP, Product Supply, Operations Strategy and Transformation Officer, while the 8-K describes it as EVP of Global Operations and Supply Chain.

The filing

CompanyPerrigo (PRGO)
Form8-K, current report
Filed with the SECJun 4, 2025, 4:54 PM ET
Accession number0001193125-25-134980

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 04, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.